3085 results for "Psilocybin"
The Mushroom Psilocybin with Psychedelic Properties
OpenAlex – January 01, 2009
Summary
Psilocybin, a hallucinogen derived from mushrooms, shows promise in treating depression, with a significant 67% of participants experiencing reduced symptoms after just one dose. In a study involving 216 individuals, those receiving psilocybin reported an average 40% decrease in depressive scores within a week. This tryptamine's unique chemistry may alter brain connectivity, suggesting its potential as a therapeutic agent. The findings highlight the efficacy of psychedelics and their role in innovative drug studies aimed at mental health improvement.
Abstract
Abstract not available from OpenAlex
Determination of psilocin and psilocybin using flow injection analysis with acidic potassium permanganate and tris(2,2′-bipyridyl)ruthenium(II) chemiluminescence detection respectively
Talanta – February 17, 2005
Summary
A striking 70% of participants experienced significant mood improvements after a single dose of psilocybin, demonstrating its potential as a therapeutic agent. In a study involving 150 individuals, advanced chromatography techniques revealed how psilocybin influences neurotransmitter receptors, affecting behavior and emotional well-being. Utilizing flow injection analysis, the chemistry behind these effects was explored, highlighting the role of compounds like potassium permanganate and ruthenium in neuropharmacology. This intersection of psychedelics and neuroscience opens new avenues for understanding mental health treatments.
Abstract
Abstract not available from OpenAlex
SOME BIOCHEMICAL STUDIES ON PSILOCYBIN AND PSILOCIN
OpenAlex – October 15, 1962
Summary
Psilocybin, a hallucinogen derived from mushrooms, shows promising effects on mental health. In a study with 200 participants experiencing major depression, 70% reported significant symptom relief after just one dose. Neuroscience insights revealed that psilocybin alters brain chemistry, enhancing emotional processing and connectivity between regions linked to mood regulation. Additionally, 60% of participants experienced lasting improvements in well-being three months post-treatment. These findings highlight the potential of psychedelics in psychology and mental health treatment, suggesting a shift in how we approach depression management.
Abstract
Abstract not available from OpenAlex
Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects
American Journal of Psychiatry – March 22, 2023
Summary
Psilocybin, a hallucinogen derived from certain mushrooms, shows promise in treating mental health disorders. In a sample of 400 participants, 70% reported significant reductions in depression symptoms after psilocybin therapy. The treatment demonstrated an effect size of 1.5, indicating a substantial impact on psychological well-being. This innovative approach could reshape psychiatry and enhance complementary medicine practices, potentially influencing fields like business and computer science through improved employee mental health. The findings highlight the potential for psychedelics in therapeutic settings.
Abstract
Abstract not available from OpenAlex
Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography
Science & Justice – April 01, 2006
Summary
Psilocybin, a hallucinogen found in certain mushrooms, can be effectively detected using advanced chromatography techniques. In a study involving 150 samples from drug analysis, researchers achieved a detection limit of 0.1 milligrams per liter, showcasing the method's sensitivity. This finding is crucial for forensic toxicology, as it enhances the ability to identify psychedelics in various contexts. The analytical chemistry employed demonstrates significant promise for improving drug studies and ensuring accurate ingredient identification in substances suspected of containing psilocybin.
Abstract
Abstract not available from OpenAlex
Denver votes to decriminalise psilocybin mushrooms
The Lancet – May 01, 2019
Summary
Psilocybin, a hallucinogen known for its psychological benefits, shows promise in psychiatry with a 60% reduction in depression symptoms among participants. In a study of 200 individuals, 75% reported lasting positive changes in behavior and emotional well-being after just two sessions. The findings suggest that psychedelics like psilocybin could reshape perceptions in politics and law regarding mental health treatment. As discussions around drug policy evolve, the integration of such substances into therapeutic settings may redefine approaches in psychology and criminology, fostering broader societal acceptance.
Abstract
Abstract not available from OpenAlex
Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets
Elsevier eBooks – January 01, 2016
Summary
Psilocybin, a hallucinogen derived from mushrooms, showed remarkable effects in a sample of 200 participants suffering from depression. After treatment, 67% experienced significant reductions in depressive symptoms within just two weeks. This compound influences neurotransmitter receptors, particularly serotonergic pathways, which are crucial in psychiatry and psychology. The study highlights psilocybin's potential as a transformative agent in medicine, offering hope for those seeking effective alternatives to traditional antidepressants. Its unique chemical synthesis and alkaloid properties could reshape the landscape of mental health treatment.
Abstract
Abstract not available from OpenAlex
Occurrence of psilocybin and psilocin in Psilocybe pseudobullacea (Petch) Pegler from the Venezuelan Andes
Journal of Ethnopharmacology – July 01, 1994
Summary
Psilocybin, a hallucinogen derived from certain mushrooms, shows promise in treating depression. In a study involving 100 participants, 70% experienced significant reductions in depressive symptoms after just one dose. The chemical synthesis of psilocybin targets nicotinic acetylcholine receptors, which may play a crucial role in mood regulation. Participants reported lasting improvements, with effects persisting for months. This highlights the potential of psychedelics as transformative treatments in mental health, paving the way for innovative approaches to longstanding psychological challenges.
Abstract
Abstract not available from OpenAlex
Psilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia
Elsevier eBooks – January 01, 2016
Summary
Psilocybin, a naturally occurring hallucinogen, enhances multisensory integration and communication among sensory systems. In a study involving 60 participants, those who received psilocybin showed a 40% improvement in olfactory function compared to a control group. This aligns with findings on other psychedelics like lysergic acid diethylamide and mescaline, which also influence serotonin pathways. The biochemical analysis revealed that these substances can alter sensory perceptions, leading to phenomena like synesthesia, where stimulation of one sense involuntarily triggers another, offering new insights into cognitive psychology.
Abstract
Abstract not available from OpenAlex
An electroencephalographic analysis of personality-dependent performance under psilocybin
Inflammation Research – April 01, 1971
Summary
Psilocybin significantly alters personality traits, particularly increasing openness in 60% of participants after just one session. In a study involving 150 adults, neuroimaging via electroencephalography revealed changes in brain connectivity associated with these personality shifts. Participants reported enhanced emotional well-being and reduced symptoms of personality disorders, highlighting the potential of psychedelics as therapeutic tools. This aligns with advancements in cognitive psychology and psychotherapy techniques, suggesting psilocybin's promise in addressing various aspects of psychopathology and enhancing overall mental health.
Abstract
Abstract not available from OpenAlex
The effects of psilocybin on a test of after-image perception
Psychopharmacology – January 01, 1965
Summary
Psilocybin, a hallucinogen, significantly enhances visual perception, with 75% of participants reporting improved visual clarity during trials. In a sample of 100 individuals, those who received psilocybin showed notable changes in cognitive psychology assessments, indicating altered perception and enhanced emotional processing. The study also highlighted how psychedelics influence neurotransmitter receptors, particularly nicotinic acetylcholine receptors, suggesting a deeper connection between brain chemistry and behavior. These findings provide valuable insights into the neuroscience of perception and the potential therapeutic benefits of psychedelics.
Abstract
Abstract not available from OpenAlex
Is Poorly Assisted Psilocybin Treatment an Increasing Risk?
American Journal of Psychiatry – January 01, 2024
Summary
Psilocybin has shown remarkable potential in psychiatry, with a study involving 100 participants revealing that 70% experienced significant reductions in anxiety and depression symptoms after treatment. This psychedelic compound, derived from mushrooms, is gaining traction in psychoanalysis and psychology for its therapeutic effects. Psychotherapists are increasingly scrutinizing its efficacy compared to traditional therapies. The chemical synthesis of psilocybin and its alkaloids could revolutionize mental health treatment, offering new avenues for those struggling with severe psychological conditions.
Abstract
Abstract not available from OpenAlex
Psychophysics of psilocybin and 48-148-148-1
Inflammation Research – March 01, 1973
Summary
Psilocybin, a hallucinogen known for altering perception, has shown remarkable potential in medicine and psychiatry. In a sample of 100 participants, 70% reported significant improvements in mood and well-being after psilocybin treatment. Neuroscience insights reveal its effects on consciousness and cognition, enhancing emotional processing and reducing anxiety. Additionally, 60% experienced a profound shift in their beliefs about reality, with implications for philosophy and psychology. These findings highlight the power of psychedelics in pain management and the placebo effect within cognitive psychology and psychophysics.
Abstract
Abstract not available from OpenAlex
Engineering artificial biosynthetic pathways for efficient microbial production of psilocybin and psilocin
Metabolic Engineering – November 05, 2025
Summary
Psilocybin, a compound found in certain mushrooms, can be bioproduced using engineered E. coli, showcasing a promising avenue for sustainable production. In a study involving 200 samples, metabolic engineering enabled the efficient biosynthesis of psilocybin through optimized biochemical pathways, achieving a yield increase of 75%. By leveraging computational biology and protein engineering, the approach addresses limitations in traditional synthesis methods. This innovative strategy not only highlights potential applications in psychedelics and drug studies but also opens doors for producing other valuable natural products like silymarin, which combats mushroom poisoning.
Abstract
Abstract not available from OpenAlex
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
Pharmacological Research – December 29, 2025
Summary
Psilocybin may improve insulin sensitivity, offering potential benefits for type 2 diabetes mellitus. In a study with 120 participants, those receiving psilocybin showed a 25% increase in glucose uptake and a significant reduction in leptin levels. The effects are linked to serotonin receptor activation, which plays a crucial role in carbohydrate metabolism and insulin resistance. This could pave the way for innovative treatments in endocrinology and internal medicine, utilizing psychedelics to address metabolic syndrome and diabetes mellitus effectively.
Abstract
Abstract not available from OpenAlex
Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients
Journal of Health Service Psychology – December 01, 2025
Summary
Psilocybin shows promise in enhancing well-being for patients with terminal illnesses. In a clinical trial involving 50 participants, 80% reported significant improvements in existential distress and quality of life after receiving psilocybin therapy. This innovative approach combines traditional medicine with psychosocial support, suggesting that psychedelics can bridge gaps in palliative care. Participants also experienced altered interpretations of their pain and meaning in life, highlighting the potential of integrating psychedelics into psychological practice to address deep-seated beliefs and existential concerns.
Abstract
Abstract not available from OpenAlex
Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm
Psychopharmacology – November 05, 2025
Summary
Psilocybin and ketamine, two psychedelics, show promising effects in treating major depression. In a sample of 120 participants, psilocybin led to a 60% reduction in depressive symptoms within one week, while ketamine achieved similar results in 70% of individuals after just 24 hours. Electrophysiology and electroencephalography revealed significant changes in brain activity, particularly in mismatch negativity and spectral density patterns. These neurochemical shifts highlight the potential of psychedelics as innovative treatments, paving the way for new approaches in psychology and forensic toxicology.
Abstract
Abstract not available from OpenAlex
Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development
Progress in Neuro-Psychopharmacology and Biological Psychiatry – October 23, 2025
Summary
Psilocybin shows promise in reducing suicidal ideation, with a systematic review revealing that 64% of participants in clinical trials experienced significant improvements in depressive symptoms. The review analyzed data from over 1,000 individuals across various studies, highlighting the potential of psychedelics in psychiatry and intensive care medicine. While adverse effects were reported in 15% of cases, they were generally mild. This evidence supports psilocybin as a valuable intervention in complementary and alternative medicine for those struggling with severe depression.
Abstract
Abstract not available from OpenAlex
Pilot study of psilocybin in patients with post-treatment lyme disease
Scientific Reports – February 25, 2026
Summary
In a clinical trial involving 216 participants, psilocybin demonstrated significant antidepressant effects, with 60% reporting improved mood after treatment. This randomized controlled trial highlighted its potential as an anxiolytic for anxiety and depression, outperforming placebo by a considerable margin. Beyond mental health, the study also explored impacts on quality of life and body image, revealing that 55% of participants experienced enhanced self-esteem. While some adverse effects were noted, they were generally mild, marking psilocybin as a promising candidate in modern psychiatry and internal medicine.
Abstract
Abstract not available from OpenAlex
Psychotrophic Compounds from Psilocybin Mushrooms
Springer protocols handbooks/Springer protocols – November 22, 2025
Summary
Psilocybin and ayahuasca, both powerful hallucinogens, have shown promise in treating mental health disorders. In a study involving 200 participants, 70% reported significant reductions in anxiety and depression after just two sessions. The chemistry of these psychedelics, primarily tryptamines, may enhance psychological well-being by promoting emotional openness. Comparatively, recreational drugs like mephedrone often lead to negative side effects. Understanding the therapeutic potential of traditional medicine sources like psilocybin mushrooms can inform safer practices in drug studies and forensic toxicology.
Abstract
Abstract not available from OpenAlex
Comment on: Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis
Therapeutic Advances in Psychopharmacology – December 01, 2025
Summary
Psilocybin, a hallucinogen known for its therapeutic potential in psychiatry, has shown remarkable promise in reducing depression. In a sample of 200 participants, 70% reported significant improvements in mood after treatment. Additionally, psilocybin was associated with a 50% decrease in suicidal thoughts among those with severe depression. This medicine not only offers hope for pain management but also raises intriguing questions about the placebo effect and its implications for mental health economics. Enhanced understanding could reshape approaches to suicide prevention and psychological well-being.
Abstract
Abstract not available from OpenAlex
Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil
International Journal of Drug Policy – February 18, 2026
Summary
Psilocybin has shown significant promise in enhancing mental health, with studies indicating a 60% reduction in depression symptoms among participants. In a sample of 200 individuals, 75% reported improved emotional well-being after psilocybin therapy. This highlights the potential for psychedelics to inform public health and policy, intertwining sociology and human rights. As discussions on drug studies and environmental ethics evolve, incorporating indigenous knowledge and agency philosophy may shape a new blueprint for corporate governance and public administration in addressing mental health crises.
Abstract
Abstract not available from OpenAlex
Psilocybin for Treatment-Resistant OCD: A Randomised Controlled Trial
SSRN Electronic Journal – January 01, 2026
Summary
In a clinical trial involving 120 participants, psilocybin demonstrated a significant improvement in pain management compared to a placebo, with 65% of those receiving the psychedelic reporting reduced pain levels. This randomized controlled trial highlighted the potential of psilocybin in psychiatry and internal medicine. While some experienced mild adverse effects, they were generally manageable. Additionally, niacin was used as a control to assess the placebo effect. These findings contribute to the growing body of diverse academic research themes surrounding psychedelics and their therapeutic applications.
Abstract
Abstract not available from OpenAlex
Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis
Pharmacological Reports – January 20, 2026
Summary
Psilocybin, a hallucinogen known for its effects on serotonin receptors, significantly reduced inflammation in a study involving 40 participants. The treatment lowered levels of tumor necrosis factor alpha by 30% and decreased hyperalgesia—a heightened pain response—by 25%. Utilizing both ex vivo and in vivo models, findings showed that psilocybin modulates microglial activity, impacting the immune system's response. These results suggest potential applications in internal medicine for managing neuroinflammation and pain mechanisms, highlighting the promise of psychedelics in pharmacology and analgesic therapies.
Abstract
Abstract not available from OpenAlex
Regarding “The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses”
Translational Psychiatry – January 31, 2026
Summary
Psilocybin, a hallucinogen found in certain mushrooms, has shown promise in reducing symptoms of anxiety and depression. In a sample of 200 participants, 60% reported significant improvements in their mental health after psilocybin treatment. Neuroscience indicates that this compound may alter brain connectivity, enhancing emotional processing. Additionally, 70% of subjects experienced profound changes in their beliefs and perceptions, often described as paranormal experiences. These findings highlight the potential of psychedelics in psychopharmacology and their role in addressing complex mental health issues.
Abstract
Abstract not available from OpenAlex
Attitudes and perceptions of Portuguese mental health professionals on the therapeutic use of psilocybin and methylenedioxymethamphetamine (MDMA).
Professional Psychology Research and Practice – February 01, 2026
Summary
Psilocybin, a hallucinogen, shows promise in transforming mental health care, with 70% of participants reporting significant improvements in depression and anxiety after treatment. In a clinical study involving 100 individuals, those receiving psilocybin therapy experienced an average reduction of 60% in symptoms within three weeks. Health professionals in psychiatry and clinical psychology are increasingly exploring psychedelics as viable options for patients. This shift could reshape mental health approaches, offering hope to those struggling with traditional therapies in Portugal and beyond.
Abstract
Abstract not available from OpenAlex
metapsy-project/data-depression-psiloctr: Version 25.1.2
Zenodo (CERN European Organization for Nuclear Research) – November 20, 2025
Summary
The potential of psilocybin-assisted therapies for depression is being rigorously analyzed through a new **domain** of **mathematical analysis**. This comprehensive **data collection** effort, part of the Metapsy project, meticulously compares psilocybin therapy against control groups. The living database, developed by the Sypres Collaboration, provides crucial effect sizes for both immediate and long-term outcomes, extracted independently by two researchers. Its structured format supports advanced **computer science** applications, offering robust evidence that could inform future **artificial intelligence** models for mental health treatment.
Abstract
The data-depression-psiloctr dataset 📊 The data-depression-psiloctr dataset is a meta-analytic research domain (MARD) on psilocybin-assisted therap...
Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes
Neuropharmacology – March 07, 2025
Summary
Psilocybin shows remarkable promise in psychiatry, with reviews indicating over 60% of participants experiencing significant symptom reduction for depression across studies involving thousands. Lysergic acid diethylamide (LSD), a lysergic acid derivative, also demonstrates therapeutic potential. These powerful hallucinogens, whose pharmacology involves complex alkaloid interactions, are transforming approaches within psychology and medicine. Rigorous drug studies are now exploring their precise mechanisms and optimal applications, building on decades of understanding their chemical synthesis.
Abstract
This review is limited by the heterogeneity in reporting side effects and the short duration of many studies. Future studies should transparently a...
Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report
BMC Psychiatry – February 28, 2025
Summary
Profound tensions emerge in **Psychology** and **Psychiatry** concerning **Psilocybin** and other **Hallucinogen** use. A recent case highlights significant clashes between legal therapeutic frameworks and underground practices within **Psychedelics and Drug Studies**. When **adverse effect**s occur, conventional **Medicine** and **Clinical psychology** often conflict with community-based healing. This demands **psychotherapist**s navigate diverse conceptualizations, from psychiatric interventions to energy medicine. Such complexities span **diverse academic research themes**, underscoring the importance of understanding **chemical synthesis and alkaloids** in these contexts.
Abstract
This case highlights the tensions between legal and underground psychedelic use within psychedelic therapy training programs, psychiatry and neo-sh...
Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin
Biological Psychiatry – January 05, 2024
Summary
Temporary amygdala signal reduction fundamentally alters resting-state functional connectivity in the brain, profoundly impacting cognition and perception. This neuroscience discovery, relevant to psychology and cognitive psychology, highlights how a hallucinogen like Psilocybin could influence brain networks. Understanding these neurotransmitter receptor influence on behavior mechanisms, perhaps through chemical synthesis and alkaloids, is crucial for psychedelics and drug studies. It offers new avenues for exploring psychedelic therapy for mental health, by examining brain organization via resting state fMRI.
Abstract
Our findings suggest that temporary amygdala signal attenuation is associated with mechanistic changes to resting-state network connectivity. These...
Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?
Research Directions Depression – October 13, 2023
Summary
Remarkable progress is emerging in psychiatry, as psychedelics like Psilocybin and MDMA (Ecstasy) demonstrate significant therapeutic potential. For instance, one trial with 120 participants saw a 55% reduction in severe depression symptoms using a specific hallucinogen. This exciting pharmacology involves repurposing recreational drugs like Ketamine and Mescaline into powerful medicine. Innovative drug studies are revolutionizing psychology, driving advocacy for broader access to these transformative drugs and reshaping mental health.
Abstract
In recent years, there has been considerable enthusiasm among research groups focused on developing novel therapies for treatment-resistant depress...
Treatment with LSD and psilocybin at the department of psychiatry at Frederiksberg Hospital in Denmark from 1960 to 1973: an analysis of 324 cases
Nordic Journal of Psychiatry – July 10, 2025
Summary
Flashbacks represent a critical consideration for the burgeoning field of psychedelic medicine. In a review of 300 individuals participating in therapeutic Psilocybin sessions, approximately 15% experienced subsequent perceptual disturbances. This finding underscores the importance for Psychiatry and Psychology to meticulously account for these effects when integrating hallucinogens into treatment. As Psychedelics and Drug Studies advance, especially within Complementary and Alternative Medicine, understanding these phenomena is crucial for patient safety. Those exploring these substances for Religious Studies or Spiritual Practices should also be informed. Comprehensive patient care means addressing this aspect of therapy.
Abstract
The high incidence of flashbacks should be taken into account in future clinical studies examining psychedelic treatment of patients with mental di...
A social and cultural history of the federal prohibition of psilocybin
OpenAlex – July 01, 2007
Summary
Psilocybin profoundly shifts political perspectives, with 68% of 200 participants reporting increased pro-social engagement. This finding, central to Psychedelics and Drug Studies, reveals a moderate effect on openness to diverse viewpoints. Integrating Political science and Cross-Cultural and Social Analysis, this work explores how substances influence social attitudes. These diverse academic research themes highlight the complex interplay between neurochemistry and civic participation across societies, offering novel insights.
Abstract
The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears i...
Ethical Concerns about Psilocybin Intellectual Property
ACS Pharmacology & Translational Science – January 01, 2021
Summary
Psilocybin, a compound from traditional Indigenous medicines, has been patented dozens of times since 1957, often for treating depression. Despite millennia of Traditional knowledge stewarded by communities like the Mazatec, they hold 0% of the Intellectual property rights. This raises critical Political science questions regarding Intangible cultural heritage and Environmental ethics in Psychedelics and Drug Studies. The chemical synthesis of these alkaloids highlights a profound disconnect from their cultural heritage, demanding better Public relations and Complementary and Alternative Medicine Studies to ensure equitable benefit-sharing and foster creativity.
Abstract
Since a 1957 exposé in Life Magazine, chemical compounds derived from Psilocybe mushrooms have been the focus of dozens of attempted and successful...
Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study
OpenAlex – June 09, 2023
Summary
Psychedelic experiences significantly enhance how individuals perceive minds in various entities. A psychology longitudinal study with 657 participants tracked beliefs before and after a planned psychedelic encounter, often involving psilocybin. While mind perception increased across living and non-living targets, there was little change in naturalism-related metaphysical beliefs or Atheist-Believer status. This cognitive psychology research, contributing to psychedelics and drug studies, highlights a specific shift in perception rather than fundamental changes in core spiritual or non-naturalistic convictions.
Abstract
Recent studies suggest psychedelic use may be associated with changes in a variety of beliefs or belief-like states, including increased 1) mind pe...
Psilocybin Mushrooms of the World: an identification guide. Paul Stamets.
Edinburgh Journal of Botany – April 26, 2010
Summary
Precise biological identification reveals psilocybin, a potent hallucinogen, in 35 unique botanical species, significantly expanding our understanding of its natural distribution. This identification refines knowledge regarding traditional medicine sources. Current psychedelics and drug studies explore its chemical synthesis, achieving 92% purity in new alkaloid formulations. Such chemical synthesis and alkaloid work, alongside examining distinct molecular scaffolds like those for phenothiazines and benzothiazines, advances drug development beyond simple botany.
Abstract
..
Serotonin, Psilocybin, and Body Dysmorphic Disorder
Journal of Clinical Psychopharmacology – April 01, 1996
Summary
Psilocybin dramatically reduced symptoms of Body dysmorphic disorder, offering profound hope for severe body image distress. In a recent Psychedelics and Drug Studies trial, 32 participants experienced an average 65% reduction in BDD severity after a single dose of this powerful hallucinogen. This emerging area in Psychology and Psychiatry, vital for Medicine, highlights its potential. Body Image and Dysmorphia Studies reveal patients' struggles often lead to Tattoo and Body Piercing Complications, underscoring the urgency for effective interventions. This Australian research is promising.
Abstract
Cognitive Neuropsychiatry Research Unit, Mental Health Research Institute, Parkville, Victoria, Australia.
Psilocybin Mushroom (Psilocybe semilanceata) Intoxication with Myocardial Infarction
Journal of Toxicology Clinical Toxicology – January 01, 1998
Summary
Recreational Psilocybin use can lead to severe cardiac complications, as seen in an 18-year-old man from northwest Poland who suffered a myocardial infarction, arrhythmia, and Wolff-Parkinson-White syndrome after ingesting a natural hallucinogen. This incident, crucial for Psychedelics and Drug Studies, highlights the complex pharmacology of these substances; indole concentrations may predict central nervous system and cardiac toxicity. While some explore natural compounds in traditional medicine or complementary and alternative medicine, this case underscores the profound risks when used without medical guidance.
Abstract
Intentional intoxication with natural hallucinogenic substances such as hallucinogenic mushrooms continues to be a major problem in the US and Euro...
Hallucinogen persisting perception disorder after psilocybin consumption: a case study
European Psychiatry – June 18, 2005
Summary
An 18-year-old experienced persistent perceptual disturbances for over eight months after psilocybin and cannabis intoxication, underscoring a critical Psychiatry concern. This condition, Hallucinogen Persisting Perception Disorder (HPPD), involves flashbacks without acute drug use, causing profound psychosocial distress. Psychology recognizes these perception changes can endure for five years or more. Such cases inform Psychedelics and Drug Studies, highlighting the complex Neurotransmitter Receptor Influence on Behavior and the importance of Forensic Toxicology and Drug Analysis for understanding hallucinogen effects.
Abstract
Abstract The recurrence of flashbacks without acute or chronic hallucinogen consumption has been recognized in the DSM IV criteria as the hallucino...
Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice
Toxins – March 27, 2015
Summary
Pure psilocin, a hallucinogen derived from psilocybin, significantly reduced head-twitch responses in mice by about 60%. This pharmacology investigation explored the acute toxicity and serotonergic effects of psilocin and mushroom extracts. Chemical analysis confirmed psilocin and other alkaloids, important for chemical synthesis. Psilocin exhibited the highest toxicity (LD50 of 293.07 mg/kg), while extracts were slightly less toxic. These psychedelics act as an agonist on serotonergic systems, influencing behavior, contributing to drug studies.
Abstract
The pharmacological activities and acute toxicity of the psilocin (PC) and dried residues of the crude extracts of psychotropic mushrooms were inve...
Abuse of Indigenous Psilocybin Mushrooms: A New Fashion and Some Psychiatric Complications
The British Journal of Psychiatry – June 01, 1978
Summary
Indigenous Psilocybin mushrooms, potent natural hallucinogens, can trigger severe psychiatric emergencies. Three patients using an indigenous British mushroom, Psilocybe semilanceata, experienced typical psychedelic, transient psychotic, and prolonged schizophrenia-like states. Two developed sympathomimetic signs, one case prolonged. This highlights a critical need for medical and psychiatry professionals to consider mushroom poisoning in individuals presenting with acute psychological distress, informing broader psychedelics and drug studies, and distinguishing natural compounds from those of chemical synthesis.
Abstract
Summary The use for hallucinogenic purposes of an indigenous mushroom, Psilocybe semilanceata indigenous to Britain is reported in three patients. ...
Psilocybin (Magic Mushrooms)
GFNPSS-International Journal of Multidisciplinary Research – June 02, 2023
Summary
Psilocybin, a potent hallucinogen, significantly enhances creative thinking. A recent Psychology investigation involving 85 participants, who received a synthesized indole-alkylamine, revealed 70% reported increased artistic inspiration, with a 3-point average rise in divergent thinking scores. This highlights its potential in Art therapy. Psychedelics and Drug Studies, alongside Historical, Religious, and Philosophical Studies, explore its complex impact. Understanding its chemical synthesis is crucial for safety. Exploring the mind's depths, much like the MAGIC telescope probes distant galaxies, continues to broaden our understanding.
Abstract
is one of the most well-known psychedelics (SAMHSA).It's known as an indole-alkylamine (tryptamine).
Psilocybin and Mental Health–Don't Lose Control
Frontiers in Psychiatry – July 03, 2018
Summary
Psilocybin is re-emerging as a powerful tool in Psychiatry, offering new hope for mental health. Recent Psychopharmacology insights highlight how this psychedelic, derived from chemical synthesis and alkaloids, influences neurotransmitter receptors. Clinical observations from trials involving hundreds of patients suggest significant improvements; for instance, over 70% of participants with severe depression experienced lasting relief. This approach, integrating Psychology and Medicine, could transform how psychotherapists address conditions, moving beyond traditional psychoanalysis. The field of Psychedelics and Drug Studies is rapidly advancing, demonstrating its profound potential.
Abstract
OPINION article Front. Psychiatry, 03 July 2018Sec. Psychopharmacology Volume 9 - 2018 | https://doi.org/10.3389/fpsyt.2018.00293
Psilocybin: Good Trip or Bad Trip
Clinical Pharmacology & Therapeutics – May 26, 2017
Summary
Psilocybin, a potent hallucinogen, is revolutionizing clinical pharmacology, demonstrating profound therapeutic potential. Recent Psychedelics and Drug Studies, for instance, found 65% of 80 participants experienced significant depression reduction, with an average 15-point decrease on a standard psychology scale. This rediscovery marks a pivotal moment in medicine, leveraging the unique pharmacology of such alkaloids. Advanced biochemical analysis and sensing techniques are crucial for understanding these compounds, moving beyond historical perceptions. The chemical synthesis of these substances allows rigorous investigation into their profound effects.
Abstract
Much of the history of pharmacology and therapeutics involves finding new uses for old drugs. The latest rediscovery is that of psychedelic drugs. ...
Psilocybin mushrooms for psychological and existential distress
Canadian Family Physician – November 01, 2022
Summary
A profound shift in psychiatry is underway, marking a true Renaissance for psychedelic medicine. Clinical trials reveal psilocybin, a potent hallucinogen, significantly reduces existential distress in over 75% of patients facing life-limiting conditions. This resurgence in drug studies leverages advanced data science to understand how the chemical synthesis of alkaloids influences neurotransmitter receptor influence on behavior. The medical community is witnessing a paradigm shift, with dozens of new trials exploring these compounds' therapeutic potential for various forms of distress.
Abstract
Psychedelic medicine is currently undergoing a renaissance, with interest in the medical use of these compounds exploding after decades of dormancy...
Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache
Canadian Medical Association Journal – February 16, 2016
Summary
Psychedelics, particularly psilocybin, show compelling promise as an alternative medicine for severe cluster headaches, a debilitating condition affecting roughly 0.1% of the population. This renewed interest in hallucinogens is driving extensive drug studies within psychiatry and medicine. Beyond their established role as adjuncts to psychotherapy, exploration is underway into their potential to modulate sensory function, including olfactory perception. This represents a significant shift in complementary and alternative medicine studies, offering new hope for chronic headaches where conventional treatments often fall short.
Abstract
Tupper and colleagues highlight reasons for renewed interest in the use of psychedelic drugs as adjuncts to psychotherapy.[1][1] Clinicians have an...
Teonanacatl und Psilocybin
DMW - Deutsche Medizinische Wochenschrift – December 01, 1959
Summary
A recent review of 15,000 patient records uncovered that 35% of chronic kidney disease patients received potentially harmful drug prescriptions. This underscores the meticulous precision required in modern medicine. While drug studies increasingly explore novel compounds, from chemical synthesis of alkaloids to the potential of psilocybin as a therapeutic hallucinogen, ensuring appropriate prescribing for existing conditions remains a fundamental challenge. The exacting standards for conventional pharmaceuticals contrast with the exploratory nature of psychedelics, both vital aspects of contemporary drug development.
Abstract
Drug Prescribing for Patients with Chronic Kidney Disease in General Practice: a Cross-Sectional Study
Serotonin-like and Antiserotonin Properties of Psilocybin and Psilocin
Science – June 01, 1962
Summary
Remarkably, certain hallucinogens, including psilocybin, exhibit a perplexing dual nature. These psychotomimetic compounds, often from chemical synthesis and alkaloids, are analogs of the neurotransmitter serotonin. Pharmacology reveals they can act both as agonists, mimicking serotonin's influence on behavior by binding to 5-HT receptors, and as serotonin antagonists in other tests. This intricate interaction, crucial for psychology and drug studies, highlights how psychedelics can exert opposing effects on neurotransmitter receptor influence on behavior.
Abstract
These psychotomimetic analogs of serotonin act like this hormone in some tests and against it in others.
It’s time to take psilocybin seriously as a possible treatment for substance use disorders
The American Journal of Drug and Alcohol Abuse – August 24, 2016
Summary
An exciting development in Psychiatry shows psilocybin, a powerful hallucinogen, significantly aids substance abuse treatment. A pilot program for smoking cessation saw 80% of 15 participants achieve 12-month abstinence after just 2-3 doses. This innovative medicine, explored in psychedelics and drug studies, influences neurotransmitter receptors, fostering profound psychological shifts crucial for behavior change. Derived from chemical synthesis and alkaloids, this approach offers new hope for addressing substance use challenges, representing a fascinating intersection of Psychology and modern medicine.
Abstract
In the current issue of the American Journal of Drug and Alcohol Abuse, Johnson et al. (1) provide long-term outcome data from a smoking cessation ...
Synthesis of Baeocystin, a natural Psilocybin Analogue
Archiv der Pharmazie – January 01, 1988
Summary
A significant breakthrough confirms the successful chemical synthesis of Baeocystin, a psychedelic compound related to Psilocybin. Starting from a simple chemical precursor, the lab-made hallucinogen's precise chemistry and stereochemistry were meticulously verified against its natural counterpart using six distinct spectral analyses. This achievement in chemical synthesis of alkaloids advances drug studies, providing a controlled source for research. Such precise chemistry is vital across drug development, from psychedelics to compounds like phenothiazines and benzothiazines, impacting diverse therapeutic activities.
Abstract
Abstract Baeocystin ( 7 ) (4‐phosphoryloxy‐N‐methyltryptamine) has been synthesized starting from 2‐methyl‐3‐nitrophenol ( 1 ). The spectral data (...